Adicet Bio, Inc. (ACET) Investor Relations Documents

Adicet Bio, Inc. (ACET) investor relations documents from the company's IR site: 16 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releaseAdicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-21Press releaseAdicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
2026-05-13Press releaseAdicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-03-12Press releaseAdicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
2026-01-30Press releaseAdicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-01-07Press releaseAdicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
2025-03-06Press releasehttps://investor.adicetbio.com/node/11361/pdf
2025-03-06Press releaseAdicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
2024-11-06Press releaseAdicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
2024-08-13Press releasehttps://investor.adicetbio.com/node/10991/pdf
2024-08-13Press releaseAdicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
2024-05-14Press releaseAdicet Reports First Quarter 2024 Financial Results and Provides Business Updates
2024-03-19Press releaseAdicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
2023-08-09Press releaseAdicet Reports Second Quarter 2023 Financial Results and Provides Business Updates
2021-08-02Press releasePress release
Press releaseAdicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B

ACET overview · ACET earnings · ACET financials · ACET KPIs · ACET ownership · ACET peers · ACET filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.